Citations (252)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (18)
Kriti Kashyap & Rita Kakkar. (2021) Exploring structural requirements of isoform selective histone deacetylase inhibitors: a comparative in silico study. Journal of Biomolecular Structure and Dynamics 39:2, pages 502-517.
Read now
Read now
Xi Pan & Jian-Hao Liu. (2021) Identification of four key biomarkers and small molecule drugs in nasopharyngeal carcinoma by weighted gene co-expression network analysis. Bioengineered 12:1, pages 3647-3661.
Read now
Read now
Kriti Kashyap & Rita Kakkar. (2020) An insight into selective and potent inhibition of histone deacetylase 8 through induced-fit docking, pharmacophore modeling and QSAR studies. Journal of Biomolecular Structure and Dynamics 38:1, pages 48-65.
Read now
Read now
Xin Tang, Yicong Xu, Lin Lu, Yang Jiao, Jianjun Liu, Linlin Wang & Hongbo Zhao. (2018) Identification of key candidate genes and small molecule drugs in cervical cancer by bioinformatics strategy. Cancer Management and Research 10, pages 3533-3549.
Read now
Read now
Lu Ding, Wan Zhang, Lili Yang, Helene Pelicano, Kaiwen Zhou, Ran Yin, Ruibin Huang & Junyi Zeng. (2018) Targeting the autophagy in bone marrow stromal cells overcomes resistance to vorinostat in chronic lymphocytic leukemia. OncoTargets and Therapy 11, pages 5151-5170.
Read now
Read now
Michiel Kroesen, Christian Büll, Paul R. Gielen, Ingrid C. Brok, Inna Armandari, Melissa Wassink, Maaike W. G. Looman, Louis Boon, Martijn H. den Brok, Peter M. Hoogerbrugge & Gosse J. Adema. (2016) Anti-GD2 mAb and Vorinostat synergize in the treatment of neuroblastoma. OncoImmunology 5:6.
Read now
Read now
Theresa D Ahrens, Sylvia Timme, Jens Hoeppner, Jenny Ostendorp, Sina Hembach, Marie Follo, Ulrich T Hopt, Martin Werner, Hauke Busch, Melanie Boerries & Silke Lassmann. (2015) Selective inhibition of esophageal cancer cells by combination of HDAC inhibitors and Azacytidine. Epigenetics 10:5, pages 431-445.
Read now
Read now
Guiyun Song, Benigno C. Valdez, Yang Li, Jose R. Dominguez, Paul Corn, Richard E. Champlin & Borje S. Andersson. (2014) The histone deacetylase inhibitor SAHA sensitizes acute myeloid leukemia cells to a combination of nucleoside analogs and the DNA-alkylating agent busulfan. Leukemia & Lymphoma 55:7, pages 1625-1634.
Read now
Read now
Michael Dickinson & Henry Miles Prince. (2014) Emerging drugs for T-cell lymphoma. Expert Opinion on Emerging Drugs 19:2, pages 201-213.
Read now
Read now
Minakshi Nihal, Nihal Ahmad & Gary S Wood. (2014) SIRT1 is upregulated in cutaneous T-cell lymphoma, and its inhibition induces growth arrest and apoptosis. Cell Cycle 13:4, pages 632-640.
Read now
Read now
Valentina Barbetti, Antonella Gozzini, Giulia Cheloni, Ilaria Marzi, Emiliano Fabiani, Valeria Santini, Persio Dello Sbarba & Elisabetta Rovida. (2013) Time- and residue-specific differences in histone acetylation induced by VPA and SAHA in AML1/ETO-positive leukemia cells. Epigenetics 8:2, pages 210-219.
Read now
Read now
Caterina Ierano, Agnes Basseville, Kenneth K.W. To, Zhirong Zhan, Robert W. Robey, Julia Wilkerson, Susan E. Bates & Stefania Scala. (2013) Histone deacetylase inhibitors induce CXCR4 mRNA but antagonize CXCR4 migration. Cancer Biology & Therapy 14:2, pages 175-183.
Read now
Read now
Simon G. Royce & Tom C. Karagiannis. (2012) Histone Deacetylases and Their Role in Asthma. Journal of Asthma 49:2, pages 121-128.
Read now
Read now
Yanis Boumber, Anas Younes & Guillermo Garcia-Manero. (2011) Mocetinostat (MGCD0103): a review of an isotype-specific histone deacetylase inhibitor. Expert Opinion on Investigational Drugs 20:6, pages 823-829.
Read now
Read now
Yong Fang, Yi Hu, Peng Wu, Beibei Wang, Yuan Tian, Xi Xia, Qinghua Zhang, Tong Chen, Xuefeng Jiang, Quanfu Ma, Gang Xu, Shixuan Wang, Jianfeng Zhou, Ding Ma & Li Meng. (2011) Synergistic Efficacy in Human Ovarian Cancer Cells by Histone Deacetylase Inhibitor TSA and Proteasome Inhibitor PS-341. Cancer Investigation 29:4, pages 247-252.
Read now
Read now
S. J. Oh, K. Lee, J. Ryu, H. E. Yu, G. Han, S. K. Park, J. S. Kang, H. M. Kim & Y. C. Kim. (2011) Evaluation of the pharmacokinetics and metabolism of a novel histone deacetylase inhibitor, KBH-A40, in rats. Xenobiotica 41:2, pages 155-163.
Read now
Read now
Paul A Marks. (2010) The clinical development of histone deacetylase inhibitors as targeted anticancer drugs. Expert Opinion on Investigational Drugs 19:9, pages 1049-1066.
Read now
Read now
Claire Bonfils, Donald R Walkinshaw, Jeffrey M Besterman, Xiang-Jiao Yang & Zuomei Li. (2008) Pharmacological inhibition of histone deacetylases for the treatment of cancer, neurodegenerative disorders and inflammatory diseases. Expert Opinion on Drug Discovery 3:9, pages 1041-1065.
Read now
Read now
Articles from other publishers (234)
Bani Kumar Jana, Mohini Singh, Rajat Subhra Dutta & Bhaskar Mazumder. (2024) Current Drug Delivery Strategies for Buccal Cavity Ailments using Mouth
Dissolving Wafer Technology: A Comprehensive Review on the Present
State of the Art. Current Drug Delivery 21:3, pages 339-359.
Crossref
Crossref
Shailendra Kumar Maurya, Asad Ur Rehman, Mohd Ali Abbas Zaidi, Parvez Khan, Shailendra K. Gautam, Juan A. Santamaria-Barria, Jawed Akhtar Siddiqui, Surinder K. Batra & Mohd Wasim Nasser. (2024) Epigenetic alterations fuel brain metastasis via regulating inflammatory cascade. Seminars in Cell & Developmental Biology 154, pages 261-274.
Crossref
Crossref
Shweta Mishra, Ekta Verma, Shailendra Patil, Dhanji P. Rajani & Asmita Gajbhiye. (2023) Exploration of quinazoline-tethered hydroxamic acid derivatives as HDAC inhibitors for anticancer activity: Design, synthesis, molecular docking, and biological evaluation. Results in Chemistry, pages 101253.
Crossref
Crossref
Bo Wang, Chu Tang, En Lin, Xiaohua Jia, Ganyuan Xie, Peiping Li, Decheng Li, Qiyue Yang, Xiaoyong Guo, Caiguang Cao, Xiaojing Shi, Baojia Zou, Chaonong Cai, Jie Tian, Zhenhua Hu & Jian Li. (2023) NIR-II fluorescence-guided liver cancer surgery by a small molecular HDAC6 targeting probe. eBioMedicine 98, pages 104880.
Crossref
Crossref
Guo Chen, Banghe Bao, Yang Cheng, Minxiu Tian, Jiyu Song, Liduan Zheng & Qiangsong Tong. (2023) Acetyl-CoA metabolism as a therapeutic target for cancer. Biomedicine & Pharmacotherapy 168, pages 115741.
Crossref
Crossref
Ping Bai, Yan Liu, Liuyue Yang, Weihua Ding, Prasenjit Mondal, Na Sang, Gang Liu, Xiaoxia Lu, Thanh Tu Ho, Yanting Zhou, Rui Wu, Vishal C. Birar, Moses Q. Wilks, Rudolph E. Tanzi, Hening Lin, Can Zhang, Weimin Li, Shiqian Shen & Changning Wang. (2023) Development and Pharmacochemical Characterization Discover a Novel Brain-Permeable HDAC11-Selective Inhibitor with Therapeutic Potential by Regulating Neuroinflammation in Mice. Journal of Medicinal Chemistry.
Crossref
Crossref
Tao Liang, Fengli Wang, Reham M. Elhassan, Yongmei Cheng, Xiaolei Tang, Wengang Chen, Hao Fang & Xuben Hou. (2023) Targeting histone deacetylases for cancer therapy: Trends and challenges. Acta Pharmaceutica Sinica B 13:6, pages 2425-2463.
Crossref
Crossref
Rourou Li, Yujia Tian, Zhenwu Yang, Yueshan Ji, Jiaqi Ding & Aixia Yan. (2022) Classification models and SAR analysis on HDAC1 inhibitors using machine learning methods. Molecular Diversity 27:3, pages 1037-1051.
Crossref
Crossref
Ruiqi Liu, Jiajun Wu, Haiwei Guo, Weiping Yao, Shuang Li, Yanwei Lu, Yongshi Jia, Xiaodong Liang, Jianming Tang & Haibo Zhang. (2023) Post‐translational modifications of histones: Mechanisms, biological functions, and therapeutic targets. MedComm 4:3.
Crossref
Crossref
Emre M. Isin. (2023) Unusual Biotransformation Reactions of Drugs and Drug Candidates. Drug Metabolism and Disposition 51:4, pages 413-426.
Crossref
Crossref
Bi Lian, Xiaosong Chen & Kunwei Shen. (2023) Inhibition of histone deacetylases attenuates tumor progression and improves immunotherapy in breast cancer. Frontiers in Immunology 14.
Crossref
Crossref
Pedro Mikael da Silva Costa, Sarah Leyenne Alves Sales, Daniel Pascoalino Pinheiro, Larissa Queiroz Pontes, Sarah Sant’Anna Maranhão, Claudia do Ó. Pessoa, Gilvan Pessoa Furtado & Cristiana Libardi Miranda Furtado. (2023) Epigenetic reprogramming in cancer: From diagnosis to treatment. Frontiers in Cell and Developmental Biology 11.
Crossref
Crossref
Xiao-yuan Song, Xiu-Wen Liu & Jia Wang. (2023) Suberoylanilide hydroxamic acid (SAHA) attenuates memory impairment in the offspring of rats exposed to sevoflurane anesthesia. Biochemical and Biophysical Research Communications 643, pages 139-146.
Crossref
Crossref
Marcelo Lima Ribeiro, Salvador Sánchez Vinces, Laura Mondragon & Gael Roué. (2023) Epigenetic targets in B- and T-cell lymphomas: latest developments. Therapeutic Advances in Hematology 14, pages 204062072311734.
Crossref
Crossref
Minnatallah Al-Yozbaki, Ibtissam Jabre, Naeem H. Syed & Cornelia M. Wilson. (2022) Targeting DNA methyltransferases in non-small-cell lung cancer. Seminars in Cancer Biology 83, pages 77-87.
Crossref
Crossref
Stefano Federico, Tuhina Khan, Anna Fontana, Simone Brogi, Rosaria Benedetti, Federica Sarno, Gabriele Carullo, Alex Pezzotta, Akella Prasanth Saraswati, Eugenia Passaro, Luca Pozzetti, Alessandro Papa, Nicola Relitti, Sandra Gemma, Stefania Butini, Anna Pistocchi, Anna Ramunno, Fabrizio Vincenzi, Katia Varani, Vanessa Tatangelo, Laura Patrussi, Cosima T. Baldari, Simona Saponara, Beatrice Gorelli, Stefania Lamponi, Massimo Valoti, Fulvio Saccoccia, Marialaura Giannaccari, Giovina Ruberti, Daniel Herp, Manfred Jung, Lucia Altucci & Giuseppe Campiani. (2022) Azetidin-2-one-based small molecules as dual hHDAC6/HDAC8 inhibitors: Investigation of their mechanism of action and impact of dual inhibition profile on cell viability. European Journal of Medicinal Chemistry 238, pages 114409.
Crossref
Crossref
Daniel Herp, Johannes Ridinger, Dina Robaa, Stephen A. Shinsky, Karin Schmidtkunz, Talha Z. Yesiloglu, Theresa Bayer, Raphael R. Steimbach, Corey J. Herbst‐Gervasoni, Annika Merz, Christophe Romier, Peter Sehr, Nikolas Gunkel, Aubry K. Miller, David W. Christianson, Ina Oehme, Wolfgang Sippl & Manfred Jung. (2022) First Fluorescent Acetylspermidine Deacetylation Assay for HDAC10 Identifies Selective Inhibitors with Cellular Target Engagement**. ChemBioChem 23:14.
Crossref
Crossref
Aishat Motolani, Matthew Martin, Steven Sun & Tao Lu. 2022. Drug Repurposing - Molecular Aspects and Therapeutic Applications. Drug Repurposing - Molecular Aspects and Therapeutic Applications.
Jianglei Li, Meihong Yu, Shifeng Fu, Deliang Liu & Yuyong Tan. (2022) Role of Selective Histone Deacetylase 6 Inhibitor ACY-1215 in Cancer and Other Human Diseases. Frontiers in Pharmacology 13.
Crossref
Crossref
Mathew Angelos, Hatcher Ballard & Stefan Barta. (2022) Advances and Personalized Approaches in the Frontline Treatment of T-Cell Lymphomas. Journal of Personalized Medicine 12:2, pages 267.
Crossref
Crossref
Heriberto Moran, Limary M. Cancel, Peigen Huang, Sylvie Roberge, Tuoye Xu, John M. Tarbell & Lance L. Munn. (2022) Glycocalyx mechanotransduction mechanisms are involved in renal cancer metastasis. Matrix Biology Plus 13, pages 100100.
Crossref
Crossref
Xiaohua Lu, Ge Yan, Mona Dawood, Sabine M. Klauck, Yoshikazu Sugimoto, Anette Klinger, Edmond Fleischer, Letian Shan & Thomas Efferth. (2021) A novel moniliformin derivative as pan-inhibitor of histone deacetylases triggering apoptosis of leukemia cells. Biochemical Pharmacology 194, pages 114677.
Crossref
Crossref
Nikolay Toshev, Diana Cheshmedzhieva & Todor Dudev. (2021) Factors governing the affinity and selectivity of histone deacetylase inhibitors for the HDAC8 enzyme active site: Implications for anticancer therapy. Journal of Physical Organic Chemistry 34:12.
Crossref
Crossref
Farkhondeh Khanjani, Leila Jafari, Somayeh Azadiyan, Sahar Roozbehi, Cobra Moradian, Javad Zahiri, Sadegh Hasannia & Reza H. Sajedi. (2021) Drug repositioning based on gene expression data for human HER2-positive breast cancer. Archives of Biochemistry and Biophysics 712, pages 109043.
Crossref
Crossref
Anna Wawruszak, Lidia Borkiewicz, Estera Okon, Wirginia Kukula-Koch, Syeda Afshan & Marta Halasa. (2021) Vorinostat (SAHA) and Breast Cancer: An Overview. Cancers 13:18, pages 4700.
Crossref
Crossref
R. Dushanan, S. Weerasinghe, D. P. Dissanayake & R. Senthilnithy. (2021)
An
In-Silico
Approach to Evaluate the Inhibitory Potency of Selected Hydroxamic Acid Derivatives on Zinc-Dependent Histone Deacetylase Enzyme
. Journal of Computational Biophysics and Chemistry 20:06, pages 603-618.
Crossref
Crossref
Bartosz Bieszczad, Damian Garbicz, Marta Świtalska, Marta K. Dudek, Dawid Warszycki, Joanna Wietrzyk, Elżbieta Grzesiuk & Adam Mieczkowski. (2021) Improved HDAC Inhibition, Stronger Cytotoxic Effect and Higher Selectivity against Leukemias and Lymphomas of Novel, Tricyclic Vorinostat Analogues. Pharmaceuticals 14:9, pages 851.
Crossref
Crossref
Tatiana Montoya, María Luisa Castejón, Rocío Muñoz-García & Catalina Alarcón-de-la-Lastra. (2021) Epigenetic linkage of systemic lupus erythematosus and nutrition. Nutrition Research Reviews, pages 1-21.
Crossref
Crossref
Dario Kringel, Sebastian Malkusch & Jörn Lötsch. (2021) Drugs and Epigenetic Molecular Functions. A Pharmacological Data Scientometric Analysis. International Journal of Molecular Sciences 22:14, pages 7250.
Crossref
Crossref
Yang Shi, Zheng Xiang, Huiyu Yang, Suliman Khan, Ruizhe Li, Siran Zhou, Saif Ullah, Jiyu Zhang & Bingrong Liu. (2021) Pharmacological targeting of TNS3 with histone deacetylase inhibitor as a therapeutic strategy in esophageal squamous cell carcinoma. Aging 13:11, pages 15336-15352.
Crossref
Crossref
Courtney M. Edwards & Rachelle W. Johnson. (2021) Targeting Histone Modifications in Bone and Lung Metastatic Cancers. Current Osteoporosis Reports 19:3, pages 230-246.
Crossref
Crossref
Tirtha K. Das, Jared Gatto, Rupa Mirmira, Ethan Hourizadeh, Dalia Kaufman, Bruce D. Gelb & Ross Cagan. (2021) Drosophila RASopathy models identify disease subtype differences and biomarkers of drug efficacy. iScience 24:4, pages 102306.
Crossref
Crossref
Clemens Zwergel, Elisabetta Di Bello, Rossella Fioravanti, Mariarosaria Conte, Angela Nebbioso, Roberta Mazzone, Gerald Brosch, Ciro Mercurio, Mario Varasi, Lucia Altucci, Sergio Valente & Antonello Mai. (2020) Novel Pyridine‐Based Hydroxamates and 2′‐Aminoanilides as Histone Deacetylase Inhibitors: Biochemical Profile and Anticancer Activity. ChemMedChem 16:6, pages 989-999.
Crossref
Crossref
Erdem Bangi, Peter Smibert, Andrew V. Uzilov, Alexander G. Teague, Sindhura Gopinath, Yevgeniy Antipin, Rong Chen, Chana Hecht, Nelson Gruszczynski, Wesley J. Yon, Denis Malyshev, Denise Laspina, Isaiah Selkridge, Huan Wang, Jorge Gomez, John Mascarenhas, Aye S. Moe, Chun Yee Lau, Patricia Taik, Chetanya Pandya, Max Sung, Sara Kim, Kendra Yum, Robert Sebra, Michael Donovan, Krzysztof Misiukiewicz, Celina Ang, Eric E. Schadt, Marshall R. Posner & Ross L. Cagan. (2021) A Drosophila platform identifies a novel, personalized therapy for a patient with adenoid cystic carcinoma. iScience 24:3, pages 102212.
Crossref
Crossref
Eline A. M. Zijtregtop, Iris van der Strate, Auke Beishuizen, Christian M. Zwaan, Marijn A. Scheijde-Vermeulen, Arianne M. Brandsma & Friederike Meyer-Wentrup. (2021) Biology and Clinical Applicability of Plasma Thymus and Activation-Regulated Chemokine (TARC) in Classical Hodgkin Lymphoma. Cancers 13:4, pages 884.
Crossref
Crossref
Nicola Relitti, A. Prasanth Saraswati, Giulia Chemi, Margherita Brindisi, Simone Brogi, Daniel Herp, Karin Schmidtkunz, Fulvio Saccoccia, Giovina Ruberti, Cristina Ulivieri, Francesca Vanni, Federica Sarno, Lucia Altucci, Stefania Lamponi, Manfred Jung, Sandra Gemma, Stefania Butini & Giuseppe Campiani. (2021) Novel quinolone-based potent and selective HDAC6 inhibitors: Synthesis, molecular modeling studies and biological investigation. European Journal of Medicinal Chemistry 212, pages 112998.
Crossref
Crossref
Lirui Wang, Chunlei Zhang, Yuping Hong, Xinhong Li, Tangan Li, Ang Gao, Shaojun Pan, Bin Liu, Han Jin & Daxiang Cui. (2020) Integrating Epigenetic Modulators in Nanofibers for Synergistic Gastric Cancer Therapy via Epigenetic Reprogramming. Nano Letters 21:1, pages 298-307.
Crossref
Crossref
Zeynep Ates-Alagoz & Adeboye Adejare. 2021. Remington. Remington
169
186
.
Mahsa Ghorbaninejad, Maliheh Khademi-Shirvan, Samaneh Hosseini & Mohamadreza Baghaban Eslaminejad. (2020) Epidrugs: novel epigenetic regulators that open a new window for targeting osteoblast differentiation. Stem Cell Research & Therapy 11:1.
Crossref
Crossref
Katarzyna Iżykowska, Karolina Rassek, Dorota Korsak & Grzegorz K. Przybylski. (2020) Novel targeted therapies of T cell lymphomas. Journal of Hematology & Oncology 13:1.
Crossref
Crossref
Fumi Murakoshi, Hironori Bando, Tatsuki Sugi, Oluyomi Stephen Adeyemi, Motohiro Nonaka, Takaaki Nakaya & Kentaro Kato. (2020) Nullscript inhibits Cryptosporidium and Toxoplasma growth. International Journal for Parasitology: Drugs and Drug Resistance 14, pages 159-166.
Crossref
Crossref
Tao Liang, Yi Zhou, Reham M. Elhassan, Xuben Hou, Xinying Yang & Hao Fang. (2020) HDAC–Bax Multiple Ligands Enhance Bax-Dependent Apoptosis in HeLa Cells. Journal of Medicinal Chemistry 63:20, pages 12083-12099.
Crossref
Crossref
I-Chung Chen, Bidyadhar Sethy & Jing-Ping Liou. (2020) Recent Update of HDAC Inhibitors in Lymphoma. Frontiers in Cell and Developmental Biology 8.
Crossref
Crossref
Kriti Kashyap & Rita Kakkar. (2020) Pharmacophore-enabled virtual screening, molecular docking and molecular dynamics studies for identification of potent and selective histone deacetylase 8 inhibitors. Computers in Biology and Medicine 123, pages 103850.
Crossref
Crossref
Eric Chen, Kelley Bohm, Mark Rosenblatt & Kai Kang. (2020) Epigenetic regulation of anterior segment diseases and potential therapeutics. The Ocular Surface 18:3, pages 383-395.
Crossref
Crossref
Chu Tang, Yang Du, Qian Liang, Zhen Cheng & Jie Tian. (2019) Development of a Novel Histone Deacetylase-Targeted Near-Infrared Probe for Hepatocellular Carcinoma Imaging and Fluorescence Image-Guided Surgery. Molecular Imaging and Biology 22:3, pages 476-485.
Crossref
Crossref
Ahmed K. ElHady, Shou-Ping Shih, Yu-Cheng Chen, Yi-Chang Liu, Nermin S. Ahmed, Adam B. Keeton, Gary A. Piazza, Matthias Engel, Ashraf H. Abadi & Mohammad Abdel-Halim. (2020) Extending the use of tadalafil scaffold: Development of novel selective phosphodiesterase 5 inhibitors and histone deacetylase inhibitors. Bioorganic Chemistry 98, pages 103742.
Crossref
Crossref
Shuangxi Liu, Zonglong Hu, Qiumeng Zhang, Qiwen Zhu, Yi Chen & Wei Lu. (2019) Co-Prodrugs of 7-Ethyl-10-hydroxycamptothecin and Vorinostat with in Vitro Hydrolysis and Anticancer Effects. ACS Omega 5:1, pages 350-357.
Crossref
Crossref
Kazuki Okubo, Makoto Isono, Kosuke Miyai, Takako Asano & Akinori Sato. (2019) Fluvastatin potentiates anticancer activity of vorinostat in renal cancer cells. Cancer Science 111:1, pages 112-126.
Crossref
Crossref
Madiha Iqbal, Tea Reljic, Ernesto Ayala, Taimur Sher, Hemant Murthy, Vivek Roy, James Foran, Han Tun, Ambuj Kumar & Mohamed A. Kharfan-Dabaja. (2020) Efficacy of Allogeneic Hematopoietic Cell Transplantation in Cutaneous T Cell Lymphoma: Results of a Systematic Review and Meta-Analysis. Biology of Blood and Marrow Transplantation 26:1, pages 76-82.
Crossref
Crossref
Hui-Wen Chiu, Ya-Ling Yeh, Sheng-Yow Ho, Yuan-Hua Wu, Bour-Jr Wang, Wei-Jan Huang, Yuan-Soon Ho, Ying-Jan Wang, Li-Ching Chen & Shih-Hsin Tu. (2019) A New Histone Deacetylase Inhibitor Enhances Radiation Sensitivity through the Induction of Misfolded Protein Aggregation and Autophagy in Triple-Negative Breast Cancer. Cancers 11:11, pages 1703.
Crossref
Crossref
Tao Liang, Xuben Hou, Yi Zhou, Xinying Yang & Hao Fang. (2019) Design, Synthesis, and Biological Evaluation of 2,4-Imidazolinedione Derivatives as HDAC6 Isoform-Selective Inhibitors. ACS Medicinal Chemistry Letters 10:8, pages 1122-1127.
Crossref
Crossref
Haiying Lu, Lan Bai, Yanping Zhou, Yongping Lu, Zhongliang Jiang & Jianyou Shi. (2019) Recent Study of Dual HDAC/PARP Inhibitor for the Treatment of Tumor. Current Topics in Medicinal Chemistry 19:12, pages 1041-1050.
Crossref
Crossref
Sankha Subhra Das, Rashmi Sinha & Nishant Chakravorty. (2019) Integrative microRNA and gene expression analysis identifies new drug repurposing candidates for fetal hemoglobin induction in β-hemoglobinopathies. Gene 706, pages 77-83.
Crossref
Crossref
Samuel Bouchet, Camille Linot, Dusan Ruzic, Danica Agbaba, Benoit Fouchaq, Joëlle Roche, Katarina Nikolic, Christophe Blanquart & Philippe Bertrand. (2019) Extending Cross Metathesis To Identify Selective HDAC Inhibitors: Synthesis, Biological Activities, and Modeling. ACS Medicinal Chemistry Letters 10:6, pages 863-868.
Crossref
Crossref
Shuangxi Liu, Kaili Zhang, Qiwen Zhu, Qianqian Shen, Qiumeng Zhang, Jiahui Yu, Yi Chen & Wei Lu. (2019) Synthesis and biological evaluation of paclitaxel and vorinostat co-prodrugs for overcoming drug resistance in cancer therapy in vitro. Bioorganic & Medicinal Chemistry 27:7, pages 1405-1413.
Crossref
Crossref
Philippe Bertrand, Christophe Blanquart & Valérie Héroguez. (2019) The ROMP: A Powerful Approach to Synthesize Novel pH-Sensitive Nanoparticles for Tumor Therapy. Biomolecules 9:2, pages 60.
Crossref
Crossref
Dan Gibson. (2019) Multi-action Pt(IV) anticancer agents; do we understand how they work?. Journal of Inorganic Biochemistry 191, pages 77-84.
Crossref
Crossref
Geunyeol Choi, Tae-Jin Yang, Sungjae Yoo, Seung-In Choi, Ji Yeon Lim, Pyung Sun Cho & Sun Wook Hwang. (2018) TRPV4-Mediated Anti-nociceptive Effect of Suberanilohydroxamic Acid on Mechanical Pain. Molecular Neurobiology 56:1, pages 444-453.
Crossref
Crossref
Shabir Ahmad GanaiShabir Ahmad Ganai. 2019. Histone Deacetylase Inhibitors — Epidrugs for Neurological Disorders. Histone Deacetylase Inhibitors — Epidrugs for Neurological Disorders
77
89
.
Allyson Flower & Oussama Abla. 2019. Resistance to Targeted Therapies in Lymphomas. Resistance to Targeted Therapies in Lymphomas
87
110
.
Dibyendu Dana, Satishkumar Gadhiya, Luce St. Surin, David Li, Farha Naaz, Quaisar Ali, Latha Paka, Michael Yamin, Mahesh Narayan, Itzhak Goldberg & Prakash Narayan. (2018) Deep Learning in Drug Discovery and Medicine; Scratching the Surface. Molecules 23:9, pages 2384.
Crossref
Crossref
Maria Cosenza & Samantha Pozzi. (2018) The Therapeutic Strategy of HDAC6 Inhibitors in Lymphoproliferative Disease. International Journal of Molecular Sciences 19:8, pages 2337.
Crossref
Crossref
Tirtha K. Das, Jessica Esernio & Ross L. Cagan. (2018) Restraining Network Response to Targeted Cancer Therapies Improves Efficacy and Reduces Cellular Resistance. Cancer Research 78:15, pages 4344-4359.
Crossref
Crossref
Mengyi Hou, Zhenglan Huang, Sicheng Chen, Hao Wang, Tianyu Feng, Shujuan Yan, Yuxi Su & Guowei Zuo. (2018) Synergistic antitumor effect of suberoylanilide hydroxamic acid and cisplatin in osteosarcoma cells. Oncology Letters.
Crossref
Crossref
Chu Tang, Yang Du, Qian Liang, Zhen Cheng & Jie Tian. (2018) Development of a Novel Ferrocenyl Histone Deacetylase Inhibitor for Triple-Negative Breast Cancer Therapy. Organometallics 37:14, pages 2368-2375.
Crossref
Crossref
Mohamed H. Aboumanei, Aly A. Abdelbary, Ismail T. Ibrahim, Mina I. Tadros & Mohamed T. El-Kolaly. (2018) Design and development of microemulsion systems of a new antineoplaston A10 analog for enhanced intravenous antitumor activity: In vitro characterization, molecular docking, 125I-radiolabeling and in vivo biodistribution studies. International Journal of Pharmaceutics 545:1-2, pages 240-253.
Crossref
Crossref
Daniela Buonvicino, Roberta Felici, Giuseppe Ranieri, Riccardo Caramelli, Andrea Lapucci, Leonardo Cavone, Mirko Muzzi, Lorena Di Pietro, Camilla Bernardini, Clemens Zwergel, Sergio Valente, Antonello Mai & Alberto Chiarugi. (2018) Effects of Class II-Selective Histone Deacetylase Inhibitor on Neuromuscular Function and Disease Progression in SOD1-ALS Mice. Neuroscience 379, pages 228-238.
Crossref
Crossref
Louise Photiou, Carrie van der Weyden, Christopher McCormack & H. Miles Prince. (2018) Systemic Treatment Options for Advanced-Stage Mycosis Fungoides and Sézary Syndrome. Current Oncology Reports 20:4.
Crossref
Crossref
Katherine B. Peters, Eric S. Lipp, Elizabeth Miller, James E. Herndon, Frances McSherry, Annick Desjardins, David A. Reardon & Henry S. Friedman. (2017) Phase I/II trial of vorinostat, bevacizumab, and daily temozolomide for recurrent malignant gliomas. Journal of Neuro-Oncology 137:2, pages 349-356.
Crossref
Crossref
Kai-Wen Hsu, Chien-Yu Huang, Ka-Wai Tam, Chun-Yu Lin, Li-Chi Huang, Ching-Ling Lin, Wen-Shyang Hsieh, Wei-Ming Chi, Yu-Jia Chang, Po-Li Wei, Shou-Tung Chen & Chia-Hwa Lee. (2018) The Application of Non-Invasive Apoptosis Detection Sensor (NIADS) on Histone Deacetylation Inhibitor (HDACi)-Induced Breast Cancer Cell Death. International Journal of Molecular Sciences 19:2, pages 452.
Crossref
Crossref
Lilach Moyal, Neta Goldfeiz, Batia Gorovitz, Ada Rephaeli, Efrat Tal, Nataly Tarasenko, Abraham Nudelman, Yael Ziv & Emmilia Hodak. (2017) AN-7, a butyric acid prodrug, sensitizes cutaneous T-cell lymphoma cell lines to doxorubicin via inhibition of DNA double strand breaks repair. Investigational New Drugs 36:1, pages 1-9.
Crossref
Crossref
Qing Zhang, Yifan Dai, Zhiming Cai & Lisha Mou. (2018) HDAC Inhibitors: Novel Immunosuppressants for Allo- and Xeno- Transplantation. ChemistrySelect 3:1, pages 176-187.
Crossref
Crossref
Jun Wang, Mei-qing Xu, Xian-liang Jiang, Xin-yu Mei & Xue-gang Liu. (2018) Histone deacetylase inhibitor SAHA-induced epithelial–mesenchymal transition by upregulating Slug in lung cancer cells. Anti-Cancer Drugs 29:1, pages 80-88.
Crossref
Crossref
Mohammed Alqinyah & Shelley B. Hooks. (2018) Regulating the regulators: Epigenetic, transcriptional, and post-translational regulation of RGS proteins. Cellular Signalling 42, pages 77-87.
Crossref
Crossref
R. Ragheb, G. Venton, R. Chelbi, N. Bonnet, T. Le Treut, V. Ivanov, C. Mercier, P. Poulin, N. Beaufils, J. Gabert, P. Suchon, P. Rihet, B. Loriod, B. Kahn-Perlès & Régis T. Costello. (2017) Vorinostat and Mithramycin A in combination therapy as an interesting strategy for the treatment of Sézary T lymphoma: a transcriptomic approach. Archives of Dermatological Research 309:8, pages 611-623.
Crossref
Crossref
Song'e Luo, Kai Ma, Hongxia Zhu, Shuren Wang, Mei Liu, Weina Zhang, Shufang Liang & Ningzhi Xu. (2017) Molecular, biological characterization and drug sensitivity of chidamide‑resistant non‑small cell lung cancer cells. Oncology Letters.
Crossref
Crossref
Andrea Lapucci, Leonardo Cavone, Daniela Buonvicino, Roberta Felici, Elisabetta Gerace, Clemens Zwergel, Sergio Valente, Antonello Mai & Alberto Chiarugi. (2017) Effect of Class II HDAC inhibition on glutamate transporter expression and survival in SOD1-ALS mice. Neuroscience Letters 656, pages 120-125.
Crossref
Crossref
Yuan-Hua Wu, Chi-Wei Hong, Yi-Ching Wang, Wei-Jan Huang, Ya-Ling Yeh, Bour-Jr Wang, Ying-Jan Wang & Hui-Wen Chiu. (2017) A novel histone deacetylase inhibitor TMU-35435 enhances etoposide cytotoxicity through the proteasomal degradation of DNA-PKcs in triple-negative breast cancer. Cancer Letters 400, pages 79-88.
Crossref
Crossref
Ran Li & Ye-Hua Gan. (2017) Inhibiting HDAC1 Enhances the Anti-Cancer Effects of Statins through Downregulation of GGTase-Iβ Expression. International Journal of Molecular Sciences 18:5, pages 1010.
Crossref
Crossref
Fengshan Li, Tiegong Wang, Zhenyong Wang, Xiongfei Chen & Ruhai Liu. (2017) Histone deacetylase inhibitor quisinostat activates caspase signaling and upregulates p53 acetylation to inhibit the proliferation of HepG2 cells. Molecular Medicine Reports 16:5, pages 6094-6101.
Crossref
Crossref
Gang Zhao, Guoliang Wang, Hongmin Bai, Tiandong Li, Fanghe Gong, Huan Yang, Jinchong Wen & Weimin Wang. (2017) Targeted inhibition of HDAC8 increases the doxorubicin sensitivity of neuroblastoma cells via up regulation of miR-137. European Journal of Pharmacology 802, pages 20-26.
Crossref
Crossref
Hui Zhang, Yu-Ping Shang, Hong-ying Chen & Jun Li. (2017) Histone deacetylases function as novel potential therapeutic targets for cancer. Hepatology Research 47:2, pages 149-159.
Crossref
Crossref
Chiara Angiolilli, Pawel A Kabala, Aleksander M Grabiec, Iris M Van Baarsen, Bradley S Ferguson, Samuel García, Beatriz Malvar Fernandez, Timothy A McKinsey, Paul P Tak, Gianluca Fossati, Paolo Mascagni, Dominique L Baeten & Kris A Reedquist. (2017) Histone deacetylase 3 regulates the inflammatory gene expression programme of rheumatoid arthritis fibroblast-like synoviocytes. Annals of the Rheumatic Diseases 76:1, pages 277-285.
Crossref
Crossref
Marjorie G. Zauderer. 2017. Asbestos and Mesothelioma. Asbestos and Mesothelioma
313
345
.
Kazuma YagiMakoto IshiiHo NamkoongHideki FujiiTakahiro AsamiShoji SuzukiTakanori AsakuraKosuke MizoguchiTetsuro KamoSadatomo TasakaSatoshi Iwata, Steven L. KunkelNaoki HasegawaTomoko Betsuyaku. (2016) Histone Deacetylase Inhibition Protects Mice Against Lethal Postinfluenza Pneumococcal Infection. Critical Care Medicine 44:10, pages e980-e987.
Crossref
Crossref
Joëlle Roche & Philippe Bertrand. (2016) Inside HDACs with more selective HDAC inhibitors. European Journal of Medicinal Chemistry 121, pages 451-483.
Crossref
Crossref
Hao Wang, Cheng Huang, Liang Zhao, Huan Zhang, Jing Mo Yang, Peng Luo, Bing-Xiang Zhan, Qing Pan, Jun Li & Bao-Long Wang. (2016) Histone deacetylase inhibitors regulate P-gp expression in colorectal cancer via transcriptional activation and mRNA stabilization. Oncotarget 7:31, pages 49848-49858.
Crossref
Crossref
Minjie Gao, Gege Chen, Houcai Wang, Bingqian Xie, Liangning Hu, Yuanyuan Kong, Guang Yang, Yi Tao, Ying Han, Xiaosong Wu, Yiwen Zhang, Bojie Dai & Jumei Shi. (2016) Therapeutic potential and functional interaction of carfilzomib and vorinostat in T-cell leukemia/lymphoma. Oncotarget 7:20, pages 29102-29115.
Crossref
Crossref
Z Meng, L-F Jia & Y-H Gan. (2015) PTEN activation through K163 acetylation by inhibiting HDAC6 contributes to tumour inhibition. Oncogene 35:18, pages 2333-2344.
Crossref
Crossref
Sister M. Lucy GanttFSGMFSGM, Christophe Decroos, Matthew S. Lee, Laura E. Gullett, Christine M. Bowman, David W. Christianson & Carol A. Fierke. (2016) General Base–General Acid Catalysis in Human Histone Deacetylase 8. Biochemistry 55:5, pages 820-832.
Crossref
Crossref
Lilach Moyal, Nataly Feldbaum, Neta Goldfeiz, Ada Rephaeli, Abraham Nudelman, Michal Weitman, Nataly Tarasenko, Batia Gorovitz, Leah Maron, Shiran Yehezkel, Iris Amitay-Laish, Ido Lubin & Emmilia Hodak. (2016) The Therapeutic Potential of AN-7, a Novel Histone Deacetylase Inhibitor, for Treatment of Mycosis Fungoides/Sezary Syndrome Alone or with Doxorubicin. PLOS ONE 11:1, pages e0146115.
Crossref
Crossref
MD. ALI ASGAR, GULSIRI SENAWONG, BANCHOB SRIPA & THANASET SENAWONG. (2016) Synergistic anticancer effects of cisplatin and histone deacetylase inhibitors (SAHA and TSA) on cholangiocarcinoma cell lines. International Journal of Oncology 48:1, pages 409-420.
Crossref
Crossref
Heather Miller, Chiemeka Ike, Jennifer Parma, Ramya P. Masand, Claire M. Mach & Matthew L. Anderson. (2016) Molecular Targets and Emerging Therapeutic Options for Uterine Leiomyosarcoma. Sarcoma 2016, pages 1-7.
Crossref
Crossref
Vincent Zwick, Alessandra Nurisso, Claudia Simões-Pires, Samuel Bouchet, Nadine Martinet, Attila Lehotzky, Judit Ovadi, Muriel Cuendet, Christophe Blanquart & Philippe Bertrand. (2016) Cross metathesis with hydroxamate and benzamide BOC-protected alkenes to access HDAC inhibitors and their biological evaluation highlighted intrinsic activity of BOC-protected dihydroxamates. Bioorganic & Medicinal Chemistry Letters 26:1, pages 154-159.
Crossref
Crossref
Sun Hongmao. 2016. A Practical Guide to Rational Drug Design. A Practical Guide to Rational Drug Design
61
108
.
Cheng Zhang, Jiang F. Zhong, Andres Stucky, Xue-Lian Chen, Michael F. Press & Xi Zhang. (2015) Histone acetylation: novel target for the treatment of acute lymphoblastic leukemia. Clinical Epigenetics 7:1.
Crossref
Crossref
Chun-wa Chung. 2015. Epigenetics for Drug Discovery. Epigenetics for Drug Discovery
192
229
.
Anderly C. ChuehJanson W.T. TseLars TögelJohn M. Mariadason. (2015) Mechanisms of Histone Deacetylase Inhibitor-Regulated Gene Expression in Cancer Cells. Antioxidants & Redox Signaling 23:1, pages 66-84.
Crossref
Crossref
Maxim Polansky, Rakhshandra Talpur, Seema Daulat, Chitra Hosing, Bouthaina Dabaja & Madeleine Duvic. (2015) Long-Term Complete Responses to Combination Therapies and Allogeneic Stem Cell Transplants in Patients With Sézary Syndrome. Clinical Lymphoma Myeloma and Leukemia 15:5, pages e83-e93.
Crossref
Crossref
Wei-Ying Kuo, Chun-Yi Wu, Luen Hwu, Jhih-Shian Lee, Cheng-Han Tsai, Kang-Ping Lin, Hsin-Ell Wang, Teh-Ying Chou, Chun-Ming Tsai, Juri Gelovani & Ren-Shyan Liu. (2015) Enhancement of tumor initiation and expression of KCNMA1, MORF4L2 and ASPM genes in the adenocarcinoma of lung xenograft after vorinostat treatment. Oncotarget 6:11, pages 8663-8675.
Crossref
Crossref
Li-hui Yin, Xiao-qun Zheng, Hai-ying Li, Lai-xi Bi, Yi-fen Shi, Ai-fang Ye, Jian-bo Wu & Shen-meng Gao. (2015) Epigenetic deregulated miR-375 contributes to the constitutive activation of JAK2/STAT signaling in myeloproliferative neoplasm. Leukemia Research 39:4, pages 471-478.
Crossref
Crossref
H. Ümit Kaniskan, Kyle D. Konze & Jian Jin. (2014) Selective Inhibitors of Protein Methyltransferases. Journal of Medicinal Chemistry 58:4, pages 1596-1629.
Crossref
Crossref
Chun-wa Chung. 2015. Multifaceted Roles of Crystallography in Modern Drug Discovery. Multifaceted Roles of Crystallography in Modern Drug Discovery
27
40
.
Iza Denis, Fatima el Bahhaj, Floraine Collette, Régis Delatouche, Fabien Gueugnon, Daniel Pouliquen, Loic Pichavant, Valérie Héroguez, Marc Grégoire, Philippe Bertrand & Christophe Blanquart. (2014) Vorinostat–Polymer Conjugate Nanoparticles for Acid-Responsive Delivery and Passive Tumor Targeting. Biomacromolecules 15:12, pages 4534-4543.
Crossref
Crossref
Fatima El Bahhaj, Jérôme Désiré, Christophe Blanquart, Nadine Martinet, Vincent Zwick, Claudia Simões-Pires, Muriel Cuendet, Marc Grégoire & Philippe Bertrand. (2014) Superacid and thiol-ene reactions for access to psammaplin analogues with HDAC inhibition activities. Tetrahedron 70:51, pages 9702-9708.
Crossref
Crossref
Hongpeng He, Xuena Liu, Dandan Wang, Yijie Wang, Lei Liu, Hao Zhou, Xuegang Luo, Nan Wang, Bingyan Ji, Yan Luo & Tongcun Zhang. (2014) SAHA inhibits the transcription initiation of HPV18 E6/E7 genes in HeLa cervical cancer cells. Gene 553:2, pages 98-104.
Crossref
Crossref
Tram Anh Tran, Jennifer Wichterman-Kouznetsova, Diana Varghese, Ruili Huang, Wenwei Huang, Matthias Becker, Christopher P. Austin, James Inglese, Ronald L. Johnson & Elisabeth D. Martinez. (2014) Identification of Small Molecule Modulators of Gene Transcription with Anticancer Activity. ACS Chemical Biology 9:11, pages 2603-2611.
Crossref
Crossref
C. Tzao, J.-S. Jin, B.-H. Chen, H.-Y. Chung, C.-C. Chang, T.-Y. Hsu & G.-H. Sun. (2014)
Anticancer effects of suberoylanilide hydroxamic acid in esophageal squamous cancer cells
in vitro
and
in vivo
. Diseases of the Esophagus 27:7, pages 693-702.
Crossref
Crossref
Gwang Hyeon Eom & Hyun Kook. (2014) Posttranslational modifications of histone deacetylases: Implications for cardiovascular diseases. Pharmacology & Therapeutics 143:2, pages 168-180.
Crossref
Crossref
Fabien Gueugnon, Pierre-François Cartron, Cedric Charrier, Philippe Bertrand, Jean-François Fonteneau, Marc Gregoire & Christophe Blanquart. (2014) New histone deacetylase inhibitors improve cisplatin antitumor properties against thoracic cancer cells. Oncotarget 5:12, pages 4504-4515.
Crossref
Crossref
Xiaoguang Li, Yingjie Zhang, Lei Zhang, Yingying Xu & Wenfang Xu. (2013) 3D QSAR and docking studies of a series of histone deacetylase inhibitors. Medicinal Chemistry Research 23:5, pages 2229-2241.
Crossref
Crossref
Lorenz H. Lehmann, Barbara C. Worst, David A. Stanmore & Johannes Backs. (2013) Histone deacetylase signaling in cardioprotection. Cellular and Molecular Life Sciences 71:9, pages 1673-1690.
Crossref
Crossref
Michael W. Van Dyke. (2014) Lysine Deacetylase (KDAC) Regulatory Pathways: an Alternative Approach to Selective Modulation. ChemMedChem 9:3, pages 511-522.
Crossref
Crossref
Lillian Kun, Francisco J. Hernandez-Ilizaliturri & Nishitha M. Reddy. (2014) Novel Therapeutic Strategies for Cutaneous T-Cell Lymphoma in Advanced Stages. Seminars in Hematology 51:1, pages 35-41.
Crossref
Crossref
Alexander Burtea & Nicholas T. Salzameda. (2014) Discovery and SAR study of a sulfonamide hydroxamic acid inhibitor for the botulinum neurotoxin serotype A light chain. Med. Chem. Commun. 5:6, pages 706-710.
Crossref
Crossref
Pablo H. Strobl-Mazzulla & Marianne E. Bronner. 2014. Neural Crest Cells. Neural Crest Cells
89
100
.
Paul A. Marks. 2015. Molecular Oncology. Molecular Oncology
912
920
.
Jörn Lötsch, Gisbert Schneider, Daniel Reker, Michael J. Parnham, Petra Schneider, Gerd Geisslinger & Alexandra Doehring. (2013) Common non-epigenetic drugs as epigenetic modulators. Trends in Molecular Medicine 19:12, pages 742-753.
Crossref
Crossref
M New, H Olzscha, G Liu, O Khan, L Stimson, J McGouran, D Kerr, A Coutts, B Kessler, M Middleton & N B La Thangue. (2013) A regulatory circuit that involves HR23B and HDAC6 governs the biological response to HDAC inhibitors. Cell Death & Differentiation 20:10, pages 1306-1316.
Crossref
Crossref
Michael J. Morris & Lisa M. Monteggia. (2013) Unique functional roles for class I and class II histone deacetylases in central nervous system development and function. International Journal of Developmental Neuroscience 31:6, pages 370-381.
Crossref
Crossref
HSUEH-TSEN CHENG & WEN-CHUN HUNG. (2013) Inhibition of proliferation, sprouting, tube formation and Tie2 signaling of lymphatic endothelial cells by the histone deacetylase inhibitor SAHA. Oncology Reports 30:2, pages 961-967.
Crossref
Crossref
Jesse E. Hanson, Hank La, Emile Plise, Yung-Hsiang Chen, Xiao Ding, Taleen Hanania, Emily V. Sabath, Vadim Alexandrov, Dani Brunner, Emer Leahy, Pascal Steiner, Lichuan Liu, Kimberly Scearce-Levie & Qiang Zhou. (2013) SAHA Enhances Synaptic Function and Plasticity In Vitro but Has Limited Brain Availability In Vivo and Does Not Impact Cognition. PLoS ONE 8:7, pages e69964.
Crossref
Crossref
James P. Parker, Hassan Nimir, Darren M. Griffith, Brian Duff, Anthony J. Chubb, Marian P. Brennan, Maria P. Morgan, Denise A. Egan & Celine J. Marmion. (2013) A novel platinum complex of the histone deacetylase inhibitor belinostat: Rational design, development and in vitro cytotoxicity. Journal of Inorganic Biochemistry 124, pages 70-77.
Crossref
Crossref
Kirsty L. Culley, Wang Hui, Matt J. Barter, Rose K. Davidson, Tracey E. Swingler, Auriane P. M. Destrument, Jenny L. Scott, Simon T. Donell, Steve Fenwick, Andrew D. Rowan, David A. Young & Ian M. Clark. (2013) Class I Histone Deacetylase Inhibition Modulates Metalloproteinase Expression and Blocks Cytokine-Induced Cartilage Degradation. Arthritis & Rheumatism 65:7, pages 1822-1830.
Crossref
Crossref
Noelia Agra, Florencia Cidre, Laura García-García, Juan de la Parra & Javier Alonso. (2013) Lysyl Oxidase Is Downregulated by the EWS/FLI1 Oncoprotein and Its Propeptide Domain Displays Tumor Supressor Activities in Ewing Sarcoma Cells. PLoS ONE 8:6, pages e66281.
Crossref
Crossref
Sarah HawtreeMunitta MuthanaAnthony G. Wilson. (2013) The role of histone deacetylases in rheumatoid arthritis fibroblast-like synoviocytes. Biochemical Society Transactions 41:3, pages 783-788.
Crossref
Crossref
Hiromi I. Wettersten & Robert H. Weiss. (2013) Potential biofluid markers and treatment targets for renal cell carcinoma. Nature Reviews Urology 10:6, pages 336-344.
Crossref
Crossref
Jahangir Amin, Antonino Puglisi, James Clarke, John Milton, Minghua Wang, Ronald M. Paranal, James E. Bradner & John Spencer. (2013) A cyclodextrin-capped histone deacetylase inhibitor. Bioorganic & Medicinal Chemistry Letters 23:11, pages 3346-3348.
Crossref
Crossref
Claudia Cosentino & Raul Mostoslavsky. (2013) Metabolism, longevity and epigenetics. Cellular and Molecular Life Sciences 70:9, pages 1525-1541.
Crossref
Crossref
Anna Laurenzana, Manjola Balliu, Cristina Cellai, Maria Novella Romanelli & Francesco Paoletti. (2013) Effectiveness of the Histone Deacetylase Inhibitor (S)-2 against LNCaP and PC3 Human Prostate Cancer Cells. PLoS ONE 8:3, pages e58267.
Crossref
Crossref
HSUEH-TSEN CHENG & WEN-CHUN HUNG. (2013) Inhibition of lymphangiogenic factor VEGF-C expression and production by the histone deacetylase inhibitor suberoylanilide hydroxamic acid in breast cancer cells. Oncology Reports 29:3, pages 1238-1244.
Crossref
Crossref
Guan-Min Jiang, Hong-Sheng Wang, Fan Zhang, Kun-Shui Zhang, Zong-Cai Liu, Rui Fang, Hao Wang, Shao-Hui Cai & Jun Du. (2013) Histone deacetylase inhibitor induction of epithelial?mesenchymal transitions via up-regulation of Snail facilitates cancer progression. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research 1833:3, pages 663-671.
Crossref
Crossref
M Kaliszczak, S Trousil, O Åberg, M Perumal, Q-D Nguyen & E O Aboagye. (2013) A novel small molecule hydroxamate preferentially inhibits HDAC6 activity and tumour growth. British Journal of Cancer 108:2, pages 342-350.
Crossref
Crossref
W Yan, S Liu, E Xu, J Zhang, Y Zhang, X Chen & X Chen. (2012) Histone deacetylase inhibitors suppress mutant p53 transcription via histone deacetylase 8. Oncogene 32:5, pages 599-609.
Crossref
Crossref
John M. Denu. 2013. Environmental Epigenomics in Health and Disease. Environmental Epigenomics in Health and Disease
163
187
.
Angela Nebbioso, Vincenzo Carafa, Rosaria Benedetti & Lucia Altucci. (2012) Trials with ‘epigenetic’ drugs: An update. Molecular Oncology 6:6, pages 657-682.
Crossref
Crossref
Li-Ping Sun, Ai-Ling Chen, Hsiao-Chiao Hung, Yin-Huan Chien, Jing-Shi Huang, Chung-Yang Huang, Yue-Wen Chen & Chia-Nan Chen. (2012) Chrysin: A Histone Deacetylase 8 Inhibitor with Anticancer Activity and a Suitable Candidate for the Standardization of Chinese Propolis. Journal of Agricultural and Food Chemistry 60:47, pages 11748-11758.
Crossref
Crossref
David S. HewingsTimothy P. C. RooneyLaura E. JenningsDuncan A. HayChristopher J. SchofieldPaul E. BrennanStefan KnappStuart J. Conway. (2012) Progress in the Development and Application of Small Molecule Inhibitors of Bromodomain–Acetyl-lysine Interactions. Journal of Medicinal Chemistry 55:22, pages 9393-9413.
Crossref
Crossref
Thomas Buchheit, Thomas Van de Ven & Andrew Shaw. (2012) Epigenetics and the Transition from Acute to Chronic Pain. Pain Medicine 13:11, pages 1474-1490.
Crossref
Crossref
Robert Knobler, Madeleine Duvic, Christiane Querfeld, David Straus, Steven Horwitz, Jasmine Zain, Francine Foss, Timothy Kuzel, Kim Campbell & Larisa Geskin. (2012)
Long‐term follow‐up and survival of cutaneous
T
‐cell lymphoma patients treated with extracorporeal photopheresis
. Photodermatology, Photoimmunology & Photomedicine 28:5, pages 250-257.
Crossref
Crossref
R.M. Izu-Belloso & J.C. García-Ruiz. (2012) Treatment of Cutaneous Lymphomas: an Update. Actas Dermo-Sifiliográficas (English Edition) 103:8, pages 694-707.
Crossref
Crossref
R.M. Izu-Belloso & J.C. García-Ruiz. (2012) Actualización terapéutica en linfomas cutáneos. Actas Dermo-Sifiliográficas 103:8, pages 694-707.
Crossref
Crossref
Chun-wa Chung & David F. Tough. (2012) Bromodomains: a new target class for small molecule drug discovery. Drug Discovery Today: Therapeutic Strategies 9:2-3, pages e111-e120.
Crossref
Crossref
Björn Hackanson, Leander Rimmele, Marco Benkißer, Mahmoud Abdelkarim, Manfred Fliegauf, Manfred Jung & Michael Lübbert. (2012) HDAC6 as a target for antileukemic drugs in acute myeloid leukemia. Leukemia Research 36:8, pages 1055-1062.
Crossref
Crossref
Paul V. LicciardiFaith A.A. KwaKatherine VerverisNatasha Di CostanzoAneta BalcerczykMimi L. TangAssam El-OstaTom C. Karagiannis. (2012) Influence of Natural and Synthetic Histone Deacetylase Inhibitors on Chromatin. Antioxidants & Redox Signaling 17:2, pages 340-354.
Crossref
Crossref
Viktor Brabec, Darren M. Griffith, Anna Kisova, Hana Kostrhunova, Lenka Zerzankova, Celine J. Marmion & Jana Kasparkova. (2012)
Valuable Insight into the Anticancer Activity of the Platinum-Histone Deacetylase Inhibitor Conjugate,
cis
-[Pt(NH
3
)
2
malSAHA
–2H
)]
. Molecular Pharmaceutics 9:7, pages 1990-1999.
Crossref
Crossref
P Peixoto, V Castronovo, N Matheus, C Polese, O Peulen, A Gonzalez, M Boxus, E Verdin, M Thiry, F Dequiedt & D Mottet. (2012) HDAC5 is required for maintenance of pericentric heterochromatin, and controls cell-cycle progression and survival of human cancer cells. Cell Death & Differentiation 19:7, pages 1239-1252.
Crossref
Crossref
Jasmine Zain. (2012) Role of Histone Deacetylase Inhibitors in the Treatment of Lymphomas and Multiple Myeloma. Hematology/Oncology Clinics of North America 26:3, pages 671-704.
Crossref
Crossref
Simon G. Royce, Katherine Ververis & Tom C. Karagiannis. (2012) Controversies Surrounding the Potential Use of Histone Deacetylase Inhibitors for the Treatment of Asthma. ISRN Pulmonology 2012, pages 1-10.
Crossref
Crossref
Graham R Leggatt & Brian Gabrielli. (2011) Histone deacetylase inhibitors in the generation of the anti‐tumour immune response. Immunology & Cell Biology 90:1, pages 33-38.
Crossref
Crossref
Matthew J Sweet, Melanie R Shakespear, Nabilah A Kamal & David P Fairlie. (2011) HDAC inhibitors: modulating leukocyte differentiation, survival, proliferation and inflammation. Immunology & Cell Biology 90:1, pages 14-22.
Crossref
Crossref
J Chang, D S Varghese, M C Gillam, M Peyton, B Modi, R L Schiltz, L Girard & E D Martinez. (2011) Differential response of cancer cells to HDAC inhibitors trichostatin A and depsipeptide. British Journal of Cancer 106:1, pages 116-125.
Crossref
Crossref
Chun-wa Chung. 2012. Progress in Medicinal Chemistry Volume 51. Progress in Medicinal Chemistry Volume 51
1
55
.
Ju-Hee Lee, Megan L. Choy & Paul A. Marks. 2012. Histone Deacetylase Inhibitors as Cancer Therapeutics. Histone Deacetylase Inhibitors as Cancer Therapeutics
39
86
.
Ruman Rahman & Richard Grundy. (2011) Histone deacetylase inhibition as an anticancer telomerase‐targeting strategy. International Journal of Cancer 129:12, pages 2765-2774.
Crossref
Crossref
Ju-Hee Lee, Megan L. Choy, Lang Ngo, Gisela Venta-Perez & Paul A. Marks. (2011) Role of checkpoint kinase 1 (Chk1) in the mechanisms of resistance to histone deacetylase inhibitors. Proceedings of the National Academy of Sciences 108:49, pages 19629-19634.
Crossref
Crossref
Francoise Halley, Jeanette Reinshagen, Bernhard Ellinger, Markus Wolf, Andrew L. Niles, Nathan J. Evans, Thomas A. Kirkland, Julia M. Wagner, Manfred Jung, Philip Gribbon & Sheraz Gul. (2011) A Bioluminogenic HDAC Activity Assay: Validation and Screening. SLAS Discovery 16:10, pages 1227-1235.
Crossref
Crossref
M.D. Cantley, D.P. Fairlie, P.M. Bartold, K.D. Rainsford, G.T. Le, A.J. Lucke, C.A. Holding & D.R. Haynes. (2011) Inhibitors of histone deacetylases in class I and class II suppress human osteoclasts in vitro. Journal of Cellular Physiology 226:12, pages 3233-3241.
Crossref
Crossref
María A. Sánchez, Tatiana González, Miguel F. Gaitán, Ángela Zuluaga, Sol B. Jiménez & Yolanda T. de Galvis. (2011) Is PUVA maintenance therapy necessary in patients with early-stage mycosis fungoides? Evaluation of a treatment guideline over a 28-month follow-up. International Journal of Dermatology 50:9, pages 1086-1093.
Crossref
Crossref
Yu Luo, Hao-Min Liu, Ming-Bo Su, Li Sheng, Yu-Bo Zhou, Jia Li & Wei Lu. (2011) Synthesis and biological evaluation of piperamide analogues as HDAC inhibitors. Bioorganic & Medicinal Chemistry Letters 21:16, pages 4844-4846.
Crossref
Crossref
Gregory W. Peek & Trygve O. Tollefsbol. (2011) The transposon-driven evolutionary origin and basis of histone deacetylase functions and limitations in disease prevention. Clinical Epigenetics 2:2, pages 97-112.
Crossref
Crossref
Yifei Liu & Andrew Xiao. (2011) Epigenetic regulation in neural crest development. Birth Defects Research Part A: Clinical and Molecular Teratology 91:8, pages 788-796.
Crossref
Crossref
Veronica Novotny-Diermayr, Nina Sausgruber, Yung Kiang Loh, Mohammed Khalid Pasha, Ramesh Jayaraman, Hannes Hentze, Wei-Peng Yong, Boon-Cher Goh, Han-Chong Toh, Kantharaj Ethirajulu, Joy Zhu & Jeanette Marjorie Wood. (2011) Pharmacodynamic Evaluation of the Target Efficacy of SB939, an Oral HDAC Inhibitor with Selectivity for Tumor Tissue. Molecular Cancer Therapeutics 10:7, pages 1207-1217.
Crossref
Crossref
Ah-Reum Seong, Jung-Yoon Yoo, KyungChul Choi, Mee-Hee Lee, Yoo-Hyun Lee, Jeongmin Lee, Woojin Jun, Sunoh Kim & Ho-Geun Yoon. (2011) Delphinidin, a specific inhibitor of histone acetyltransferase, suppresses inflammatory signaling via prevention of NF-κB acetylation in fibroblast-like synoviocyte MH7A cells. Biochemical and Biophysical Research Communications 410:3, pages 581-586.
Crossref
Crossref
Samuel S. Oliver & John M. Denu. (2011) Disrupting the Reader of Histone Language. Angewandte Chemie International Edition 50:26, pages 5801-5803.
Crossref
Crossref
Samuel S. Oliver & John M. Denu. (2011) Störung von Histon‐Ablesern. Angewandte Chemie 123:26, pages 5921-5923.
Crossref
Crossref
Darren M. Griffith, Brian Duff, Kyrill Y. Suponitsky, Kevin Kavanagh, Maria P. Morgan, Denise Egan & Celine J. Marmion. (2011) Novel trans-platinum complexes of the histone deacetylase inhibitor valproic acid; synthesis, in vitro cytotoxicity and mutagenicity. Journal of Inorganic Biochemistry 105:6, pages 793-799.
Crossref
Crossref
Silvia Consalvi, Valentina Saccone, Lorenzo Giordani, Giulia Minetti, Chiara Mozzetta & Pier Lorenzo Puri. (2011) Histone Deacetylase Inhibitors in the Treatment of Muscular Dystrophies: Epigenetic Drugs for Genetic Diseases. Molecular Medicine 17:5-6, pages 457-465.
Crossref
Crossref
Hestia S. Mellert, Timothy J. Stanek, Stephen M. Sykes, Frank J. RauscherIIIIII, David C. Schultz & Steven B. McMahon. (2011) Deacetylation of the DNA-binding Domain Regulates p53-mediated Apoptosis. Journal of Biological Chemistry 286:6, pages 4264-4270.
Crossref
Crossref
Konrad A. Bode & Alexander H. Dalpke. (2011) HDAC inhibitors block innate immunity. Blood 117:4, pages 1102-1103.
Crossref
Crossref
Hae Jin Kee & Hyun Kook. (2011) Roles and Targets of Class I and IIa Histone Deacetylases in Cardiac Hypertrophy. Journal of Biomedicine and Biotechnology 2011, pages 1-10.
Crossref
Crossref
Stefan David & Stephen J. Meltzer. 2011. Pre-Invasive Disease: Pathogenesis and Clinical Management. Pre-Invasive Disease: Pathogenesis and Clinical Management
41
63
.
Carly St Germain, Anna O'Brien & Jim Dimitroulakos. (2010) Activating Transcription Factor 3 regulates in part the enhanced tumour cell cytotoxicity of the histone deacetylase inhibitor M344 and cisplatin in combination. Cancer Cell International 10:1.
Crossref
Crossref
Jitesh Pratap, Jacqueline Akech, John J. Wixted, Gabriela Szabo, Sadiq Hussain, Meghan E. McGee-Lawrence, Xiaodong Li, Krystin Bedard, Robinder J. Dhillon, Andre J. van Wijnen, Janet L. Stein, Gary S. Stein, Jennifer J. Westendorf & Jane B. Lian. (2010) The Histone Deacetylase Inhibitor, Vorinostat, Reduces Tumor Growth at the Metastatic Bone Site and Associated Osteolysis, but Promotes Normal Bone Loss. Molecular Cancer Therapeutics 9:12, pages 3210-3220.
Crossref
Crossref
N. Reynoird, S. Rousseaux & S. Khochbin. (2010) Perturbations épigénétiques et cancer : nouvelles stratégies anticancéreuses. Bulletin du Cancer 97:11, pages 1265-1274.
Crossref
Crossref
Giovanni Di Bernardo, Nicola Alessio, Carmela Dell'Aversana, Fiorina Casale, Diana Teti, Marilena Cipollaro, Lucia Altucci & Umberto Galderisi. (2010) Impact of histone deacetylase inhibitors SAHA and MS‐275 on DNA repair pathways in human mesenchymal stem cells. Journal of Cellular Physiology 225:2, pages 537-544.
Crossref
Crossref
Paul A. Marks. (2010) Histone deacetylase inhibitors: A chemical genetics approach to understanding cellular functions. Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms 1799:10-12, pages 717-725.
Crossref
Crossref
Donald J. AbrahamP. Angibaud, K. Van Emelen & J. Arts. 2003. Burger's Medicinal Chemistry and Drug Discovery. Burger's Medicinal Chemistry and Drug Discovery
49
82
.
Michael J. Morris, Aroon S. Karra & Lisa M. Monteggia. (2010) Histone deacetylases govern cellular mechanisms underlying behavioral and synaptic plasticity in the developing and adult brain. Behavioural Pharmacology 21:5-6, pages 409-419.
Crossref
Crossref
Claudia Blattmann, Susanne Oertel, Volker Ehemann, Markus Thiemann, Peter E. Huber, Marc Bischof, Olaf Witt, Hedwig E. Deubzer, Andreas E. Kulozik, Jürgen Debus & Klaus-J. Weber. (2010) Enhancement of Radiation Response in Osteosarcoma and Rhabomyosarcoma Cell Lines by Histone Deacetylase Inhibition. International Journal of Radiation Oncology*Biology*Physics 78:1, pages 237-245.
Crossref
Crossref
J.-H. Lee, M. L. Choy, L. Ngo, S. S. Foster & Paul A. Marks. (2010) Histone deacetylase inhibitor induces DNA damage, which normal but not transformed cells can repair. Proceedings of the National Academy of Sciences 107:33, pages 14639-14644.
Crossref
Crossref
Displaying 200 of 252 citing articles. Use the download link below to view the full list of citing articles.
Download full citations list